Patents/Assignees

BAYER PHARMA AKTIENGESELLSCHAFT

40 patents in portfolio

US11992481utility2024
Use of 2-substituted Indazoles for the Treatment and Prophylaxis of Autoimmune Diseases
0 cites
US11976334utility2024
Inhibitor of ATR Kinase for Use in a Method of Treating a Hyper-proliferative Disease
0 cites
USRE049860reissue2024
Process for Preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and Purification Thereof for Use as Pharmaceutical Active Ingredient
0 cites
US11905270utility2024
Carboxylic Acid Aromatic Amides as Antagonists of Bradykinin B1 Receptor
0 cites
USRE049826reissue2024
Method for the Preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the Purification Thereof for Use as an Active Pharmaceutical Ingredient
0 cites
US11884660utility2024
Substituted Oxopyridine Derivative
0 cites
US11806404utility2023
Site Specific Homogeneous with KSP Inhibitors
0 cites
US11701347utility2023
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for Treating Diffuse Large B-cell Lymphoma
0 cites
USRE049575reissue2023
Method for the Preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the Purification Thereof for Use as an Active Pharmaceutical Ingredient
0 cites
US11690911utility2023
Combination of ATR Kinase Inhibitors and PD-1/PD-L1 Inhibitors
0 cites
US11691986utility2023
PTEFB Inhibiting Macrocyclic Compounds
0 cites
US11684621utility2023
Combination Containing Sgc Stimulators and Mineralocorticoid Receptor Antagonists
0 cites
US11684672utility2023
Combinations of Copanlisib with Anti-pd-1 Antibody
0 cites
US11685714utility2023
Prodrugs of Cytotoxic Active Agents Having Enzymatically Cleavable Groups
0 cites
US11667675utility2023
MASP Inhibitory Compounds and Uses Thereof
0 cites
US11660301utility2023
Combination of ATR Kinase Inhibitors with PARP Inhibitors
0 cites
US11660351utility2023
Antibody Drug Conjugates (adcs) Having Enzymatically Cleavable Groups
0 cites
US11643469utility2023
Specific Antibody-drug-conjugates (adcs) with KSP Inhibitors and Anti-cd123-antibodies
0 cites
US11628433utility2023
Metering Device
0 cites
US11542245utility2023
Preparative Process
0 cites

← PreviousPage 2 of 2